2nd Aug 2011 18:15
Director/PDMR Shareholding
August 2, 2011 - Shire plc , the global specialty biopharmaceutical company announces the following dealings by Persons Discharging Managerial Responsibility in Shire plc ordinary shares of 5p ("Shares") and American Depository Shares ("ADSs"). One ADS is equal to three Shares.
Exercise of Stock Appreciation Rights ("SAR Award")
The Company was notified on August 2, 2011 of the exercise of the following SAR Awards which were granted under Part A of the Shire Portfolio Share Plan.
Type of Number of Exercise Number of Number of Sale price security Shares/ price Shares/ Shares/ ADSs ADSs sold ADSs released exercised Graham Shares 88,000 £8.675 51,174 51,174 £20.233 Hetherington1
Angus Russell² Shares 74,800 £9.97 39,522 39,522 £21.140
Matthew Emmens3 ADSs 78,8254 $64.10 29,438 29,438 $102.145 ADSs 30,9105 $58.51 13,232 13,232 $102.145
1 The SAR Award granted in 2008 to Mr Hetherington was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on August 2, 2011.
² The SAR Award granted in 2008 to Mr Russell was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on August 1, 2011.
3 The SAR Awards, which were exercised on August 1, 2011, were granted in 2007 and 2008 to Mr Emmens, whilst he held the position of Chief Executive Officer of the Company.
4 The SAR Award granted in 2007 was subject to performance criteria measured over the performance period 2007 to 2009. Based on the performance criteria, 84% of the SAR Award vested.
5 The SAR Award granted in 2008 was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested.
Exercise of Share Options
The Company was notified on August 2, 2011, of the exercise on August 1, 2011, of the following option which was granted to Tatjana May in 2004 under the 2000 Executive Share Option Scheme. Ms May chose to use a net settled cashless exercise facility run by the Company.
Number of Exercise Number of Number of Sale price Shares price Shares Shares sold granted received Tatjana May 128,755 £5.26 97,033 97,033 £21.238 Release of ADSsIn addition, on August 2, 2011, the Company was notified of the release toMatthew Emmens on August 1, 2011, of the ADSs awarded in 2008 under theExecutive Annual Incentive Plan. This award was in respect of performance inthat year whilst Mr Emmens held the position of Chief Executive Officer of theCompany.Name of Director Type of Number of ADSs Number of ADSs Sale price Security released sold to satisfy tax liabilities Matthew Emmens ADSs 6,471 2,511 $102.507 Resulting Interests
After the above transactions, Angus Russell, Matthew Emmens, Graham Hetherington and Tatjana May hold the following interests.
Type of Number of Options SAR PSA Restricted security Shares/ADSs Awards Awards Shares/ADSs Matthew Emmens ADSs 50,429 - - - - Shares 92,874 - - - - Angus Russell ADSs - - 168,742 121,292 11,415 Shares 131,330 - 404,301 221,685 37,814 Graham Shares 4,000 1,240 317,687 301,833 28,080 Hetherington Tatjana May Shares 86,126 151,108 138,379 78,433 25,975
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony GuthrieDeputy Secretary
For further information please contact:
Investor Eric Rojas [email protected] +1 781 482 0999 Relations Sarah Elton-Farr [email protected] +44 1256 894157
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
XLONRelated Shares:
Shire